Revance Therapeutics Inc’s recently made public that its Chief Commercial Officer Jordan Erica unloaded Company’s shares for reported $9096.0 on Apr 16 ’24. In the deal valued at $3.80 per share,2,392 shares were sold. As a result of this transaction, Jordan Erica now holds 114,864 shares worth roughly $ 0.43 million.
Then, Schilke Tobin sold 9,361 shares, generating $47,204 in total proceeds. Upon selling the shares at $5.04, the CFO now owns 192,666 shares.
Before that, Sjuts Dustin S sold 9,211 shares. Revance Therapeutics Inc shares valued at $46,446 were divested by the President at a price of $5.04 per share. As a result of the transaction, Sjuts Dustin S now holds 167,550 shares, worth roughly $0.63 million.
Mizuho downgraded its Revance Therapeutics Inc [RVNC] rating to a Neutral from a Buy in a research note published on January 29, 2024; the price target was decreased to $9 from $16. A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in early January from “a Buy” to “a Neutral”. Exane BNP Paribas also remained covering RVNC and has increased its forecast on August 16, 2023 with a “Neutral” recommendation from previously “an Underperform” rating. Morgan Stanley started covering the stock on October 11, 2022. It rated RVNC as “an Equal-weight”.
Price Performance Review of RVNC
On Friday, Revance Therapeutics Inc [NASDAQ:RVNC] saw its stock fall -0.26% to $3.78. Over the last five days, the stock has lost -8.47%. Revance Therapeutics Inc shares have fallen nearly -57.00% since the year began. Nevertheless, the stocks have fallen -88.04% over the past one year. While a 52-week high of $37.98 was reached on 01/02/24, a 52-week low of $3.62 was recorded on 04/18/24. SMA at 50 days reached $5.21, while 200 days put it at $10.51. A total of 1.65 million shares were traded, compared to the trading of 1.6 million shares in the previous session.
Levels Of Support And Resistance For RVNC Stock
The 24-hour chart illustrates a support level at 3.70, which if violated will result in even more drops to 3.63. On the upside, there is a resistance level at 3.86. A further resistance level may holdings at 3.95. The Relative Strength Index (RSI) on the 14-day chart is 29.91, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.45, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 88.21%. Stochastics %K at 8.98% indicates the stock is a buying.
The most recent change occurred on September 22, 2022 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $33 price target.
